Effective immediately, Anti-Thyroglobulin (Anti-TgAb) requests if received in conjunction with Thyroglobulin Tumor Marker (Tg-TM) requests, will be canceled. Tg-TM tests are sent to Mayo Medical Laboratory; where both Tg-TM and Anti-TgAb are performed and resulted as part of the Tg-TM order. This is a laboratory best practice as anti-thyroglobulin autoantibodies (Anti-TgAb), which occur in 15% to 30% of thyroid cancer patients, could lead to misleading Tg results (falsely positive or falsely negative).
Questions may be directed to Dr. David Alter, using the “Contact Us” link above.
As of Thursday, November 7th, pediatric reference intervals for alkaline phosphatase were changed at Spectrum Health Regional Laboratory to reflect the reference intervals stated by the assay’s manufacturer, Roche Diagnostics. Their values are consistent with recommendations from CALIPER studies on pediatric reference intervals.
Effective November 5, 2017, the 1,25-Dihydroxyvitamin D test will have its name changed to Calcitriol (1,25-Dihydroxyvitamin D) in the Epic, Cerner and eSHare systems.
On September 21, 2017, Hepatitis A Total Antibodies, Serum, send out to Mayo Medical Laboratories, was discontinued by Mayo. This has been replaced with Mayo test Hepatitis A IgG Antibody, Serum. Please order test as a reference miscellaneous in all systems.
In mid-September 2017, Spectrum Health Regional Laboratory Immunology department in collaboration with Spectrum Health Adult and Pediatric Rheumatology have made some adjustments to antinuclear antibody (ANA) testing (see below) options.
On June 27th 2017, Spectrum Health Regional Laboratory (SHRL) will be switching instrument/vendors that perform the Cyclic Citrullinated Peptide Antibody (anti-CCP) IgG assay. We will be switching from the INOVA platform to the PHADIA-250 platform.
On May 1, 2017, Spectrum Health Regional Laboratory adjusted the reference range for C-Reactive Protein (CRP) from ≤10 mg/L to ≤5.0 mg/L.
On May 17, 2017, the US Food and Drug Administration (FDA) issued a safety communication warning against using venous samples on Point of Care Magellan Diagnostics LeadCare Testing System devices (LeadCare, LeadCare II, LeadCare Plus, and LeadCare Ultra). Venous specimens appear to be at risk for having falsely low results. Only Capillary (“finger stick” or “heel stick”) specimen types should be used.
IF YOUR OFFICE IS USING ANY OF THE MAGELLAN LEADCARE TESTING SYSTEM DEVICES: please DISCONTINUE the use of VENOUS specimens for testing.
The diagnostic evaluation of allergic disease occurs in the context of a patient’s complete clinical presentation. Important factors include, age, clinical signs and symptoms, relevant allergen exposures, and the performance characteristics (sensitivity, specificity, and predictive values) of the allergy tests themselves. Allergy tests yield information about sensitization to allergens, which is not always equivalent to allergic hypersensitivity (i.e., sensitivity); thus, interpretation in the context of clinical history is essential for accurate diagnosis.